The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Optimizing CAR T-cell therapies for thoracic cancers
Prasad Adusumilli, MD, FACS, Memorial Sloan Kettering Cancer Center, New York, NY, describes strategies to optimize chimeric antigen receptor (CAR) T-cell therapies for thoracic cancers including lung cancer and mesothelioma. Existing co-stimulatory molecules such as CD28 and 4–1BB have been utilized in CAR T-cell therapies for hematological malignancies and have been assessed in lung cancer. Additional targets for mesothelioma under development include MAGEA4, mesothelin, and CA125. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
